Luminnova CoVID-19 Treatment Protocols

The CoVID-19 protocols employed by Luminnova Health primarily utilize methylene blue photodynamic therapy and orally ingested methylene blue. Photodynamic therapy deactivates the CoVID-19 virus and other infectious agents at key entry points in the nose and mouth. The efficacy of methylene blue photodynamic therapy has been documented in peer-reviewed pre-clinical and clinical studies.

Photodynamic therapy is well known for its capacity to treat cancer and resistant infections. PDT has a broad spectrum of action, successfully addressing bacterial, fungal, parasitic, and viral infections. It also offers the advantage of a strong safety profile confirmed over many decades of use.

Red light and methylene blue offer remarkable health benefits. Both treatment methods can alleviate CoVID-19 symptoms in their own right but when combined, they exert a powerful effect to destroy infectious agents including the CoVID-19 virus. This is called photodynamic inactivation.

The remarkable effectiveness of photodynamic inactivation is evident in blood banks, where this method has been a trusted means to eliminate numerous hazardous pathogens in blood plasma before transfusion.

The Luminnova protocols can be applied in 3 main contexts:

After HIGHER RISK EXPOSURE: close social, or work related contact. See our Covid Defense Protocols.

As an EARLY INTERVENTION immediately after the onset of ANY symptoms suggestive of an upper respiratory tract infection.

As affirmed by clinical studies conducted in Germany and the Bahamas, it can be employed in cases of CONFIRMED CoVID-19 or OTHER UPPER RESPIRATORY TRACT INFECTIONS.

Our covid-19 Journey

In early 2020, a double-blind randomized clinical study sponsored by the German government, explored the use of methylene blue photodynamic viral inactivation (MBPDI) for treating CoVID-19. Professor Detlef Schikora and Dr. Juliette Hepburn co-authored an interim publication of the findings.

The study assessed 1200 patients, with 600 receiving MBPDI and the remaining 600 given a placebo (no active MBPDI treatment). The findings were remarkably positive, revealing an 83% reduction in hospitalization, 90% reduction in ICU admission, and a 90% decrease in deaths within the MBPDI group compared to the placebo group.

Impressed by the notably successful results, the Ministry of Health for North Rhine-Westphalia in Germany expressed enthusiasm in a letter endorsing the treatment. They further conveyed their intention to offer this protocol to all CoVID-19 patients in their region. Sadly this was never followed through.

In 2020, Luminnova Health introduced the German MBPDI treatment to the Bahamas. Despite its effectiveness, the treatment required close contact between the infected patient and healthcare provider. This posed a challenge given the highly infectious nature of CoVID-19.

To enhance patient access, Dr. Juliette Hepburn designed a home-based treatment device and a methylene blue treatment kit, to facilitate the Luminnova Home Care CoVID-19 program.

Significant reduction in symptoms and rapid recovery was observed using the Luminnova Home Care kits.

Based on this positive experience, Dr. Hepburn was granted approval to conduct a clinical study by the National CoVID-19 Ethics Committee. The study was initiated at the start of the CoVID-19 Delta wave in the Bahamas. At this point patients were presenting with extremely high viral loads and severe disease.

In response to this dramatic escalation in disease, Dr. Hepburn further adapted the protocol to include methylene blue tablets and red light photobiomodulation therapy.  These additional interventions showed remarkable benefits in reducing inflammation, accelerating healing of damaged tissues, and enhancing the anti-viral response.

Our published study using this newly adapted protocol documented substantial reductions in viral load over short periods, coupled with swift clinical recovery.

An excerpt from the study summary is included below:

“…Although our pilot subjects had significant co-morbidities, extremely high viral loads and moderately severe symptoms during the Delta phase of the pandemic, the response to treatment was highly encouraging. Rapid reductions in viral loads were observed and negative PCR tests were documented within a median of 4 days. These laboratory findings occurred in parallel with significant clinical improvement, mostly within 12–24 h of commencing the treatment protocol. There were no significant adverse effects and none of the subjects who completed the protocol required in-patient hospitalization. The outcomes were similarly encouraging at one-year follow-up with virtual absence of “long COVID” symptoms or of COVID-19 re-infection. Our results indicate that the protocols may be a safe and promising approach to challenging COVID-19 disease. Moreover, due its broad spectrum of activity, this approach has the potential to address the prevailing and future COVID-19 variants and other infections transmitted via the upper respiratory tract….”

Following the standardization of the Luminnova Health Upper Respiratory Protocol, a subsequent case series utilizing the complete protocol was documented and will be published separately. The outcomes were even more promising than the exploratory cases, with the majority of patients recovering and showing confirmed negative PCR tests within 72 hours, despite initially having extremely high viral loads.

Luminnova Health Upper Respiratory Care

In collaboration with other healthcare providers, Luminnova Health continues to provide support for patients suffering with CoVID-19 infection and other upper respiratory tract infections. As opposed to other single target anti-viral measures, the Luminnova Health protocol is able to target multiple CoVID-19 strains and other upper respiratory tract infections, including RSV and influenza. The key is early treatment.

Fortunately, the Omicron variants have proven to be much milder than previous CoVID-19 variants. However we strongly advise timely treatment to clear the virus as early and as completely as possible in order to minimize possible short term and long term effects from CoVID-19 infection. Furthermore, there is always a chance that more virulent strains may arise in the future.

PLEASE NOTE that our CoVID-19 protocols are offered ONLY via a Remote Home Care Program and we do not offer CoVID-19 treatments in our office. If you think you may be ill please  DO NOT ENTER THE OFFICE as this may put our other patients at risk.